Table 2.
The baseline characteristics in T2DM patients with various MTNR1B rs10830963 genotypes before treatment with nateglinide (n = 200)
| Parameters | MTNR1B rs10830963 genotype | P value | ||
|---|---|---|---|---|
| CC | CG | GG | ||
| N (men/women) | 70(40/30) | 90(48/42) | 40(23/17) | 0.850Δ |
| Age (years) | 47.81 ± 10.82 | 48.01 ± 12.04 | 47.09 ± 13.92 | 0.921 |
| BMI (kg/m2) | 26.41 ± 3.24 | 25.43 ± 3.31 | 26.59 ± 4.11 | 0.104 |
| WHR | 0.92 ± 0.06 | 0.91 ± 0.06 | 0.92 ± 0.08 | 0.552# |
| FPG (mmol/L) | 9.61 ± 2.01 | 9.91 ± 2.79 | 10.82 ± 1.79 | 0.034* |
| PPG (mmol/L) | 15.36 ± 2.46 | 14.21 ± 4.39 | 14.69 ± 5.71 | 0.224 |
| FINS (mU/L) | 8.56 ± 5.39 | 7.37 ± 6.99 | 7.53 ± 6.39 | 0.477# |
| PINS (mU/L) | 30.01 ± 17.10 | 28.11 ± 20.51 | 33.51 ± 17.49 | 0.320 |
| HOMA-IR | 3.27 ± 1.30 | 3.09 ± 3.21 | 4.01 ± 2.47 | 0.160 |
| HbA1c (%) | 9.71 ± 1.97 | 9.11 ± 2.62 | 9.95 ± 2.04 | 0.098 |
| TG (mmol/L) | 2.25 ± 1.38 | 2.31 ± 2.13 | 1.97 ± 1.52 | 0.596 |
| TC (mmol/L) | 5.21 ± 1.29 | 4.99 ± 1.31 | 5.49 ± 1.51 | 0.143 |
| HDL-c (mmol/L) | 1.28 ± 0.95 | 1.33 ± 0.59 | 1.41 ± 0.29 | 0.645 |
| LDL-c (mmol/L) | 3.45 ± 0.68 | 3.61 ± 1.19 | 3.80 ± 0.93 | 0.199# |
BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol
Data are given as (mean ± SD). P values represent statistical differences among the three different genotypes by the one-way ANOVA. ΔP values are determined by the Pearson chi-square test. #P values are determined by the Kruskal–Wallis test. *P < 0.05